Thromb Haemost 2000; 83(02): 356-357
DOI: 10.1055/s-0037-1613810
Letters to the Editor
Schattauer GmbH

Monitoring Platelet Inhibition during Chronic Oral Platele Glycoprotein IIb/IIIa Blockade: Are We Missing Somethintg?

Victor L. Serebruany
1   Sinai Center for Thrombosis Research, Johns Hopkins University, Baltimore, Maryland, USA
,
Marcus E. McKenzie
1   Sinai Center for Thrombosis Research, Johns Hopkins University, Baltimore, Maryland, USA
,
Douglas J. Levin
1   Sinai Center for Thrombosis Research, Johns Hopkins University, Baltimore, Maryland, USA
,
Paul A. Gurbel
1   Sinai Center for Thrombosis Research, Johns Hopkins University, Baltimore, Maryland, USA
› Author Affiliations
Further Information

Publication History

Received 22 July 1999

Accepted after resubmission 23 September 1999

Publication Date:
11 December 2017 (online)

 

 
  • References

  • 1 Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hillman RS, Coller BS. Rapid Platelet-Function Assay. An Automated and Quantitative Cartridge-Based Method. Circulation 1999; 99: 620-25.
  • 2 Kundu SK, Heilman EJ, Sio R, Garcia C, Ostgaard RA. Characterization of an In Vitro Platelet Function Analyzer, PFA-100TM. Clin Appl Thromb Hemost 1996; 02: 241-9.
  • 3 The EPIC Investigators. Use of the monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk angioplasty. N Engl J Med 1994; 330: 956-61.
  • 4 Simpfendorfer C, Kottke-Marchant K, Lowrie M, Anders RJ, Burns DM, Miller DP, Cove CS, DeFranco AC, Ellis SG, Moliterno DJ, Raymond RE, Sutton JM, Topol EJ. First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation 1997; 96: 76-81.
  • 5 Vorchheimer DA, Fuster V. Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety. Circulation 1998; 97: 312-4.
  • 6 Xiao Z, Theroux P, Frojmovic MM. Modulation of platelet-neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GP IIb/IIIa receptor. Thromb Haemost 1999; 81: 281-5.